Cargando…

Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report

BACKGROUND: Heparin is commonly recommended for warfarin-induced skin necrosis; however, there is currently no established therapy for this disease. We present a serious case of warfarin-induced skin necrosis that was successfully treated with oral rivaroxaban, a factor Xa inhibitor. CASE SUMMARY: A...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamada, Momoka, Kenzaka, Tsuneaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940348/
https://www.ncbi.nlm.nih.gov/pubmed/31911909
http://dx.doi.org/10.12998/wjcc.v7.i24.4285
_version_ 1783484335537520640
author Kamada, Momoka
Kenzaka, Tsuneaki
author_facet Kamada, Momoka
Kenzaka, Tsuneaki
author_sort Kamada, Momoka
collection PubMed
description BACKGROUND: Heparin is commonly recommended for warfarin-induced skin necrosis; however, there is currently no established therapy for this disease. We present a serious case of warfarin-induced skin necrosis that was successfully treated with oral rivaroxaban, a factor Xa inhibitor. CASE SUMMARY: A 48-year-old woman was admitted to the hospital for cellulitis of the right lower extremity. After antibiotic treatment, she developed pain and swelling of the left lower extremity, and deep vein thrombosis of both lower extremities was diagnosed. She was treated with a continuous heparin injection; subsequently, oral warfarin was concomitantly administered. Heparin was terminated after the therapeutic range was reached. On the following day, the patient had swelling and pain in the left lower extremity. In addition to decrease in protein S activity due to systemic lupus erythematosus, warfarin also reduced protein C activity, resulting in further hypercoagulation and skin necrosis. Warfarin was discontinued, and continuous heparin injection was resumed. Although the patient had to undergo amputation of the distal end of her left foot, continuous heparin injection was switched to oral rivaroxaban, and she was eventually discharged from the hospital in remission. CONCLUSION: Administration of direct oral anticoagulants instead of warfarin is important in patients with decreased protein S and C activity.
format Online
Article
Text
id pubmed-6940348
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-69403482020-01-07 Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report Kamada, Momoka Kenzaka, Tsuneaki World J Clin Cases Case Report BACKGROUND: Heparin is commonly recommended for warfarin-induced skin necrosis; however, there is currently no established therapy for this disease. We present a serious case of warfarin-induced skin necrosis that was successfully treated with oral rivaroxaban, a factor Xa inhibitor. CASE SUMMARY: A 48-year-old woman was admitted to the hospital for cellulitis of the right lower extremity. After antibiotic treatment, she developed pain and swelling of the left lower extremity, and deep vein thrombosis of both lower extremities was diagnosed. She was treated with a continuous heparin injection; subsequently, oral warfarin was concomitantly administered. Heparin was terminated after the therapeutic range was reached. On the following day, the patient had swelling and pain in the left lower extremity. In addition to decrease in protein S activity due to systemic lupus erythematosus, warfarin also reduced protein C activity, resulting in further hypercoagulation and skin necrosis. Warfarin was discontinued, and continuous heparin injection was resumed. Although the patient had to undergo amputation of the distal end of her left foot, continuous heparin injection was switched to oral rivaroxaban, and she was eventually discharged from the hospital in remission. CONCLUSION: Administration of direct oral anticoagulants instead of warfarin is important in patients with decreased protein S and C activity. Baishideng Publishing Group Inc 2019-12-26 2019-12-26 /pmc/articles/PMC6940348/ /pubmed/31911909 http://dx.doi.org/10.12998/wjcc.v7.i24.4285 Text en ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Case Report
Kamada, Momoka
Kenzaka, Tsuneaki
Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report
title Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report
title_full Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report
title_fullStr Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report
title_full_unstemmed Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report
title_short Successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: A case report
title_sort successful treatment of warfarin-induced skin necrosis using oral rivaroxaban: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6940348/
https://www.ncbi.nlm.nih.gov/pubmed/31911909
http://dx.doi.org/10.12998/wjcc.v7.i24.4285
work_keys_str_mv AT kamadamomoka successfultreatmentofwarfarininducedskinnecrosisusingoralrivaroxabanacasereport
AT kenzakatsuneaki successfultreatmentofwarfarininducedskinnecrosisusingoralrivaroxabanacasereport